FDA calendar · September 2019 · built from SEC filings

PDUFA dates September 2019: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in September 2019. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in September 2019

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

September 2019: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
September 5, 2019Fosaprepitant Dimeglumine (fosaprepitant dimeglumine)TEVAFDA approval—ApprovedopenFDA Drugs@FDA
September 10, 2019Gvoke Kit (glucagon)XERSFDA approval—ApprovedopenFDA Drugs@FDA
September 12, 2019XPHOZAH® (tenapanor)ARDXFDA approval—ApprovedopenFDA Drugs@FDA
September 20, 2019Wegovy (semaglutide)NVOFDA approval—ApprovedopenFDA Drugs@FDA
September 30, 2019Breztri Aerosphere (budesonide; formoterol fumarate; glycopyrrolate)AZNComplete Response Letter—CRL issuedFDA Complete Response Letters

September 2019: dated readouts

No events in this view.

Questions

What PDUFA dates are in September 2019?

0 PDUFA dates fell in September 2019. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.